Preview

Проблемы Эндокринологии

Расширенный поиск

Рекомендации по диагностике и лечению гипогонадизма (дефицита тестостерона) у мужчин. Проект

https://doi.org/10.14341/probl201561560-71

Полный текст:

Аннотация

Гипогонадизм у мужчин, определяемый как снижение уровня тестостерона в сыворотке крови в сочетании с характерными симптомами и/или признаками (подробно описанны далее), может наблюдаться при патологических изменениях яичек и/или гипофиза, таких как синдром Клайнфельтера, синдром Кальмана, а также у мужчин с идиопатическими, метаболическими или ятрогенными нарушениями, приводящими к дефициту андрогенов. Эти рекомендации не охватывают всего диапазона патологий, обусловливающих развитие гипогонадизма (дефицита тестостерона), а фокусируются на его клинических вариантах, которые составляют большую часть случаев гипогонадизма, наблюдающихся у мужчин.

Об авторах

Иван Иванович Дедов
ФГБУ «Эндокринологический научный центр» Минздрава России
Россия
доктор медицинских наук, профессор, академик РАН, директор ФГБУ ЭНЦ Минздрава РФ


Галина Афанасьевна Мельниченко
ФГБУ «Эндокринологический научный центр» Минздрава России
Россия
доктор медицинских наук, профессор, академик РАН, директор Института клинической эндокринологии ФГБУ ЭНЦ Минздрава РФ


Роман Викторович Роживанов
ФГБУ «Эндокринологический научный центр» Минздрава России
Россия
доктор медицинских наук, ведущий научный сотрудник отделения Андрологии и урологии


Дмитрий Геннадьевич Курбатов
ФГБУ «Эндокринологический научный центр» Минздрава России
Россия
доктор медицинских наук, профессор, заведующий отделением урологии и андрологии ФГБУ ЭНЦ Минздрава РФ


Список литературы

1. “Андрология. Мужское здоровье и дисфункция репродуктивной системы”. Под общ. ред. Нишлага Э., Бере Г.М. М. 2005;554 [Nishlaga E, Bere GM. eds. Andrology. Men’s health and reproductive system dysfunction. Moscow. 2005;554/ (In Russ.)].

2. Trinick TR, feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptomatic testosterone deficiency in men. The aging male. 2015;14(1):10-15. doi:10.3109/13685538.2010.511325.

3. Kaufman jm, vermeulen a. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr rev. 2005;26(6):833-876. doi:10.1210/er.2004-0013.

4. Wu fcw, tajar a, pye sr, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the european male aging study. J clin endocrinol metab. 2008;93(7):2737-2745. doi:10.1210/jc.2007-1972.

5. Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93(10):3870-3877. doi:10.1210/jc.2008-0021.

6. Савельева Л.В.., Роживанов Р.В., Шурдумова Б.О., Фадеев В.В. “Нормогонадотропный гипогонадизм у мужчин с ожирением”. //Ожирение и метаболизм. 2009;6:3:39-42. [Savel’eva LV, Rozhivanov RV, Shurdumova BO, Fadeev VV. Normogonadotropic hypogonadism in men with obesity. Obesity and metabolism. 2009;6(3):39-42. (In Russ.)]. doi:10.14341/2071-8713-5243.

7. Behre HM, Nieschlag E, Partsch C-J, et al. Diseases of the hypothalamus and the pituitary gland. 2010;169-192. doi:10.1007/978-3-540-78355-8_12.

8. Pitteloud n, durrani s, raivio t, sykiotis gp. Complex genetics in idiopathic hypogonadotropic hypogonadism. Front horm res. 2010;39:142-153. doi:10.1159/000312700.

9. Tuttelmann f, gromoll j. Novel genetic aspects of klinefelter’s syndrome. Mol hum reprod. 2010;16(6):386-395. doi:10.1093/molehr/gaq019.

10. Pühse g, secker a, kemper s, et al. Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int j androl. 2011;34(5pt2):e351-e357. doi:10.1111/j.1365-2605.2010.01123.x.

11. Wang c, nieschlag e, swerdloff r, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU and ASA recommendations. Eur urol. 2009;55(1):121-130. doi:10.1016/j.eururo.2008.08.033.

12. Buchter D, Behre H, Kliesch S, Nieschlag E. Pulsatile gnrh or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. European Journal of Endocrinology. 1998;139(3):298-303. doi:10.1530/eje.0.1390298.

13. Sykiotis GP, Hoang X-H, Avbelj M, et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab. 2010;95(6):3019-3027. doi:10.1210/jc.2009-2582.

14. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-4247. doi:10.1210/jc.2007-1245.

15. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the massachusetts male aging study. J Clin Endocr Metab. 2002;87(2):589-598. doi:10.1210/jcem.87.2.8201.

16. Huhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Practice & Research Clinical Endocrinology & Metabolism. 2006;20(4):561-576. doi:10.1016/j.beem.2006.09.003.

17. Singh R, singh L, thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian Journal of Andrology. 2007;9(2):147-179. doi:10.1111/j.1745-7262.2007.00250.x.

18. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocr Metab. 2010;95(6):2536-2559. doi:10.1210/jc.2009-2354.

19. Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations, and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endocr Metab. 2007;92(2):405-413. doi:10.1210/jc.2006-1864.

20. Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocr Metab. 2010;95(10):4542-4548. doi:10.1210/jc.2010-1314.

21. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the framingham heart study and applied to three geographically distinct cohorts. J Clin Endocr Metab. 2011;96(8):2430-2439. doi:10.1210/jc.2010-3012.

22. Dohle GR, Arver S, Bettocchi C, et al. Eau 2014 guideline on male hypogonadism. Isbn: 978-90-79754-83-0. European association of urology; 2014. Available from: http://www.uroweb.org/gls/pdf/16_male_hypogonadism_lr%20ii.pdf [last accessed 8 dec 2014].

23. Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. doi:10.1056/nejmoa0911101.

24. Lejeune H, Huyghe E, Droupy S. Diminution du désir sexuel et déficit en testostérone chez l’homme. Prog Urol. 2013;23(9):621-628. doi:10.1016/j.purol.2013.01.019.

25. Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. The Aging Male. 2015;15(4):187-197. doi:10.3109/13685538.2012.729110.

26. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3 suppl):14-22.

27. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocr Metab. 1999;84(10):3666-3672. doi:10.1210/jcem.84.10.6079.

28. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of shbg in middle-aged men compared with those in young men. Clin Endocrinol (Oxf). 2003;58(6):710-717. doi:10.1046/j.1365-2265.2003.01772.x.

29. Tajar A, Mcbeth J, Lee DM, et al. Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older european men. Pain. 2011;152(7):1495-1501. doi:10.1016/j.pain.2011.01.048.

30. Araujo AB, O’donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the massachusetts male aging study. J Clin Endocr Metab. 2004;89(12):5920-5926. doi:10.1210/jc.2003-031719.

31. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28(3 suppl):28-31.

32. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocr Metab. 2006;91(11):4335-4343. doi:10.1210/jc.2006-0401.

33. Moore C, Huebler D, Zimmermann T, et al. The aging males’ symptoms Scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46(1):80-87. doi:10.1016/j.eururo.2004.01.009.

34. Zengerling F, Schrader AJ, Cronauer MV, et al. The «aging males’ symptoms» Scale (AMS): predictive value for lowered circulating androgens. Aging Male. 2012;15(4):253-257. doi:10.3109/13685538.2012.729232.

35. Lee C-P, Jiang J-R, Chen Y, et al. The «aging males’ symptoms» (AMS) Scale assesses depression and anxiety. The Aging Male. 2015;16(3):97-101. doi:10.3109/13685538.2013.807428.

36. Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and international index of erectile function-5 questionnaires. The Aging Male. 2015;15(2):111-114. doi:10.3109/13685538.2011.646342.

37. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104-120. doi:10.3275/8061.

38. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin d status: the european male ageing study. European Journal of Endocrinology. 2011;166(1):77-85. doi:10.1530/eje-11-0743.

39. Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the testim registry in the us (trius). The Aging Male. 2015;15(1):14-21. doi:10.3109/13685538.2011.606513.

40. Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocr Metab. 2012;97(5):1554-1562. doi:10.1210/jc.2011-3020.

41. Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid. 2011;21(1):5-11. doi:10.1089/thy.2010.0092.

42. Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ. 2010;341(aug31 1):c4462-c4462. doi:10.1136/bmj.c4462.

43. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Practice & Research Clinical Endocrinology & Metabolism. 2011;25(2):221-238. doi:10.1016/j.beem.2010.08.013.

44. Knegtering H, van der Moolen AEGM, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28:109-123. doi:10.1016/s0306-4530(02)00130-0.

45. Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218. doi:10.1007/s11102-008-0106-6.

46. Роживанов Р.В. “Синдром гипогонадизма у мужчин”. //Ожирение и метаболизм. 2014;11:2:24-31. [Rozhivanov RV. Syndrome of hypogonadism in males. Obesity and Metabolism. 2014;11(2):30-34. (In Russ.)]. doi:10.14341/omet2014230-34.

47. Дедов И.И., Калинченко С.Ю. “Возрастной андрогенный дефицит у мужчин”. М.: Практическая медицина. 2006. [Dedov II, Kalinchenko SYu. Andropause in men. Moscow: prakticheskaya meditsyna. 2006. (In Russ.)].

48. Роживанов Р.В., Шурдумова Б.О., Парфенова Н.С., Савельева Л.В. “Комплексный подход к лечению ожирения и метаболического синдрома у мужчин”. //Ожирение и метаболизм. 2009;6:4:38-41. [Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel’eva LV. Kompleksnyy podkhod k lecheniyu ozhireniyai metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009;6(4):38-41. (In Russ.)]. doi:10.14341/2071-8713-4877.

49. Роживанов Р.В. “Эффективная терапия и ошибки в лечении эндокринных нарушений в андрологии”. В кн.: Эндокринология. Фармакотерапия без ошибок. Под ред. акад. РАН и РАМН Дедова И.И., акад. РАМН Мельниченко Г.А. М. 2013;615-625. [Rozhivanov RV. Effective therapy and errors in treatment of endocrine disorders in andrology. In: Dedov II, Melnichenko GA (eds.). Endocrinology. Pharmacotherapy without errors. M. 2013;615-625. (In Russ.)].

50. Роживанов Р.В. “Эндокринные нарушения половой функции у мужчин”. В кн.: Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ. Под ред. ака. РАН и РАМН Дедова И.И., акад. РАМН Мельниченко Г.А. Второе издание, исправленное и дополненное. М. 2013;754-775. [Rozhivanov RV. Endocrine disorders of sexual function in men. In: Dedov II, Mel’nochenko GA (eds.). Rational pharmacotherapy of diseases of the endocrine system and metabolic disorders. 2nd ed. M. 2013;754-775. (In Russ.)].

51. Mclachlan RI, O’Donnell L, Meachem SJ, et al. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl. 2002;23(2):149-162. doi:10.1002/j.1939-4640.2002.tb02607.x.

52. Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. 2009;92(2):594-604. doi:10.1016/j.fertnstert.2008.07.1720.

53. Whitten SJ, Nangia AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril. 2006;86(6):1664-1668. doi:10.1016/j.fertnstert.2006.05.042.

54. Moon DG, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido®) in testosterone deficiency syndrome in korean: a multicenter prospective study. The Journal of Sexual Medicine. 2010;7(6):2253-2260. doi:10.1111/j.1743-6109.2010.01765.x.

55. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a metaanalysis of randomized, placebo-controlled trials. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.2005;60(11):1451-1457. doi:10.1093/gerona/60.11.1451.

56. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010;31(5):457-465. doi:10.2164/jandrol.109.009597.

57. Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi:10.2147/cia.s4466.

58. Swerdloff RS, Wang C. Transdermal androgens: pharmacology and applicability to hypogonadal elderly men. J Endocrinol Invest. 2005;28(3 suppl):112-116.

59. Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev. 2005;14(9):2257-2260. doi:10.1158/1055-9965.epi-04-0715.

60. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):e1172-e1181.

61. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. J Am Coll Cardiol.2009;54(10):919-927. doi:10.1016/j.jacc.2009.04.078.

62. Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008;56(11):1991-1999. doi:10.1111/j.1532-5415.2008.01927.x.

63. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675-685. doi:10.1530/eje-11-0221.

64. Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and metaanalysis of randomized placebo-controlled trials. J Clin Endocr Metab. 2006;91(6):2011-2016. doi:10.1210/jc.2006-0036.

65. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-293. doi:10.1111/j.1365-2265.2005.02339.x.

66. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Syst Biol Reprod Med. 2007;53(6):353-357. doi:10.1080/01485010701730880.

67. Haider A, Gooren LJG, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes. 2009;118(03):167-171. doi:10.1055/s-0029-1202774.

68. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. doi:10.1530/eje.1.02166.

69. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515. doi: 10.1155/2014/683515.

70. Moon du g, park mg, lee sw, et al. The efficacy and safety of testosterone undecanoate (nebido((r))) in testosterone deficiency syndrome in korean: a multicenter prospective study. J sex med. 2010;7(6):2253-2260. Doi: 10.1111/j.1743-6109.2010.01765.x.

71. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med. 2006;3(4):727-735. doi:10.1111/j.1743-6109.2006.00267.x.

72. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572-2582. doi:10.1111/j.1743-6109.2010.01859.x.

73. Zitzmann M, Mattern A, Hanisch J, et al. Ipass: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10(2):579-588. doi:10.1111/j.1743-6109.2012.02853.x.

74. Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289-305. doi:10.1097/01.pra.0000358315.88931.fc.

75. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572-2582. doi:10.1111/j.1743-6109.2010.01859.x.

76. Zitzmann M, Weckesser M, Schober O, Nieschlag E. Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp Clin Endocrinol Diabetes. 2001;109(5):302-304. doi: 10.1055/s-2001-16351.

77. Etgen T, Sander D, Bickel H, Forstl H. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int. 2011;108(44):743-750. doi:10.3238/arztebl.2011.0743.

78. Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, Dickinson BD. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep. 2010;24(5):1115-1120.

79. Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi:10.1007/s10549-005-9074-y.

80. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108(3):418-424. doi:10.1002/ijc.11572.

81. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21(1):9-23. doi:10.1038/ijir.2008.31.

82. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-2361. doi:10.1001/jama.296.19.2351.

83. Endogenous H, Prostate Cancer Collaborative G, Roddam AW, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170-183. doi:10.1093/jnci/djm323.

84. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi:10.1210/jc.2009-2575.

85. Pearl JA, Berhanu D, Francois N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828-1833. doi:10.1016/j.juro.2013.05.111.

86. Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011;14(1):53-58. doi:10.3109/13685538.2010.518178.

87. Yassin DJ, El Douaihy Y, Yassin AA, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol. 2014;32(4):1049-1054. doi:10.1007/s00345-013-1187-z.

88. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29-39. doi:10.1016/s0025-6196(11)60964-6.

89. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi:10.1517/14740338.2014.950653.

90. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. doi:10.1056/nejmoa1000485.

91. Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med. 2007;4(5):1241-1246. doi:10.1111/j.1743-6109.2007.00553.x.

92. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi:10.1111/j.1365-2141.2005.05535.x.

93. Morgentaler A, Benesh JA, Denes BS, et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med. 2014;11(11):2818-2825. doi:10.1111/jsm.12657.

94. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482-492. doi:10.1056/nejmra022251.

95. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29-39. doi:10.1016/s0025-6196(11)60964-6.


Для цитирования:


Дедов И.И., Мельниченко Г.А., Роживанов Р.В., Курбатов Д.Г. Рекомендации по диагностике и лечению гипогонадизма (дефицита тестостерона) у мужчин. Проект. Проблемы Эндокринологии. 2015;61(5):60-71. https://doi.org/10.14341/probl201561560-71

For citation:


Dedov I.I., Mel'nichenko G.A., Rozhivanov R.V., Kurbatov D.G. The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project. Problems of Endocrinology. 2015;61(5):60-71. (In Russ.) https://doi.org/10.14341/probl201561560-71

Просмотров: 186


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)